BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BriaCell and BriaPro have entered into a definitive purchase agreement for the exclusive license to develop and commercialize Soluble CD80 as a biologic agent for cancer treatment and associated assets. BriaCell originally secured the license from the University of Pennsylvania in 2014. The transaction is expected to provide BriaCell with significant upfront cash and potential future milestone payments.